GF Fund Management’s BridgeBio Pharma BBIO Stock Holding History

GF Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Sell	4,103 -225	-5%	-$15.8K	﹤0.01%	240
2026 Q1	$321K	Buy	4,328 +542	+14%	+$39.3K	0.01%	245
2025 Q4	$290K	Sell	3,786 -327	-8%	-$21.5K	﹤0.01%	257
2025 Q3	$214K	Sell	4,113 -726	-15%	-$35.4K	﹤0.01%	286
2025 Q2	$209K	Hold	4,839	–	–	﹤0.01%	315
2025 Q1	$167K	Buy	4,839 +871	+22%	+$29.4K	﹤0.01%	333
2024 Q4	$109K	Buy	+3,968	New	+$103K	﹤0.01%	325

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

GF Fund Management's BBIO Position: Q2 2026 in Review

GF Fund Management reduced its BridgeBio Pharma (BBIO) stake by 5.2% in Q2 2026, selling an estimated $15.8K and leaving 4,103 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #240.

GF Fund Management first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $321K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

GF Fund Management held 4,103 shares of BridgeBio Pharma worth $306K as of Q2 2026.
GF Fund Management sold 225 BridgeBio Pharma shares in Q2 2026, an estimated $15.8K.
BridgeBio Pharma made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #240 holding.
GF Fund Management first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's BridgeBio Pharma position peaked at $321K in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.